Jaguar Health investor relations material

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company has a lead product candidate Mytesi, which is commercialized in the United States for the prevention of hemorrhagic cystitis in patients with cancer receiving certain types of chemotherapy; for the treatment of Noninfectious Diarrhea in adult patients living with HIV/AIDS receiving antiretroviral therapy; and for reduction of severity, frequency and duration of diarrhea.